Billionaire Profile
Viktor Kharitonin
Global Rank
#459

Image: kremlin.ru | CC BY 4.0 | via Wikimedia Commons

Viktor Kharitonin

CEO, Pharmaceuticals
RUSSIA
Real-Time Net Worth
$7.856B
Estimated based on Pharmaceuticals stock value as of March 6, 2026
0% (24h)
Age
53
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
RUSSIA

Biography

Viktor Kharitonin is a prominent Russian billionaire and entrepreneur, primarily known for his significant contributions to the pharmaceutical industry. His estimated net worth is $7.5 billion as of early February 2026. Kharitonin is the co-founder and Chairman of Pharmstandard, a leading Russian pharmaceutical company. His career is highlighted by the creation of Pharmstandard with Roman Abramovich in 2003, taking the company public in London in 2008 and then private again in 2016. He is also involved in various ventures including owning the Nürburgring race track in Germany and has recently acquired other companies. Primarily residing in Moscow, Kharitonin's wealth source stems from pharmaceuticals and related investments.

Fact Checked
Verified by Editorial Team
Live Data
Updated 3/6/2026

Wealth Over Time

In-Depth Profile

Early Life and Education

Viktor Vladimirovich Kharitonin was born on November 20, 1972, in Novosibirsk, Russia. Not much information is available about his childhood. He holds a degree from Novosibirsk State University.

Rise to Success

Kharitonin's career began in the early 1990s amidst significant economic and political changes in Russia. He co-founded Pharmstandard with Roman Abramovich in 2003 by combining five factories. Pharmstandard quickly became a leading pharmaceutical company, manufacturing and exporting numerous drugs. In 2008, Pharmstandard was listed on the London Stock Exchange. Kharitonin, along with Egor Kulkov, took Pharmstandard private again in 2016.

Key Business Strategies

Kharitonin's strategies focused on expanding Pharmstandard's portfolio and market reach. He acquired the Nürburgring race track in 2014 and expanded his portfolio by acquiring TSS group in 2021. He also holds stakes in other pharmaceutical companies, OTCPharm, Biocad, and Generium. Furthermore, Kharitonin has diversified his investments by acquiring the Frankfurt-Hahn Airport.

Philanthropy

Kharitonin's philanthropic efforts are focused on improving access to healthcare and supporting medical research. He has funded programs for cancer prevention and treatment, and also supports healthcare infrastructure development, including the construction and modernization of hospitals. Additionally, he supports educational institutions and initiatives promoting scientific research and innovation.

Career Milestones

2003

Co-founded Pharmstandard

Co-founded Pharmstandard with Roman Abramovich and others, a major pharmaceutical firm in Russia.

2008

Pharmstandard IPO

Successfully listed Pharmstandard on the London Stock Exchange.

2014

Acquired Nürburgring

Acquired the Nürburgring race track in Germany.

2016

Privatized Pharmstandard

Took Pharmstandard private, delisting from the London Stock Exchange.

2021

Acquired TSS Group

Expanded portfolio by acquiring TSS group through Augment Investments.

2023

Acquired Frankfurt-Hahn Airport

Bought the bankrupt Frankfurt–Hahn Airport.

Philanthropy & Social Impact

Healthcare

Healthcare Support

Not specified

Funding programs for cancer prevention and treatment, and supporting healthcare infrastructure development.

Education

Educational Initiatives

Not specified

Supports educational institutions and initiatives promoting scientific research and innovation.

Controversies & Challenges

2022

Allegations of Sanction Evasion

Accused of avoiding sanctions by relocating his firm, Augment Investments, from Cyprus to Oktyabrsky Island in Russia.

2024

Corruption Allegations

Pharmaceutical companies owned by Viktor Kharitonin are implicated in corruption schemes organized by Deputy Prime Minister of the Russian Federation Tatyana Golikova and her stepson Vladimir Khristenko.